If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ™ (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is laboratory monitoring required when a patient is taking Omvoh™ (mirikizumab-mrkz)?
Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment with mirikizumab. Monitor thereafter according to routine patient management.
The prescribing information for mirikizumab does not have a recommendation for other laboratory monitoring, including the monitoring of albumin or prealbumin levels or serum concentrations of mirikizumab.
Enclosed Prescribing Information
Date of Last Review: May 30, 2023